BHCM
SUPN icon

Brevan Howard Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Brevan Howard Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$605K Sell
11,695
-101,499
-90% -$5.17M 0.01% 1189
2025
Q4 		$5.63M Buy
113,194
+101,747
+889% +$4.95M 0.06% 215
2025
Q3 		$547K Sell
11,447
-24,658
-68% -$993K ﹤0.01% 1249
2025
Q2 		$1.14M Buy
36,105
+3,707
+11% +$119K 0.01% 1005
2025
Q1 		$1.06M Buy
32,398
+24,877
+331% +$882K 0.01% 475
2024
Q4 		$272K Buy
+7,521
New +$265K ﹤0.01% 811

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's SUPN Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 90% in Q1 2026, selling an estimated $5.17M and leaving 11,695 shares worth $605K. The position accounts for 0.01% of the portfolio, ranked #1189.

Brevan Howard Capital Management first reported a position in SUPN in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.63M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Brevan Howard Capital Management held 11,695 shares of Supernus Pharmaceuticals worth $605K as of Q1 2026.
  • Brevan Howard Capital Management sold 101,499 Supernus Pharmaceuticals shares in Q1 2026, an estimated $5.17M.
  • Supernus Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1189 holding.
  • Brevan Howard Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Brevan Howard Capital Management's Supernus Pharmaceuticals position peaked at $5.63M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.